Monogram Orthopedics issues 3D-printed FDA-approved implants unique to each patient’s anatomy.
“By 2027 50 [percent] of knee replacement surgeries will be performed robotically. Monogram is currently the only company offering FDA-approved, 3D-printed, patient-specific implants that, in the future, will be inserted with active milling robots,” Benjamin Sexson, Monogram’s CEO, said in a May 9 press release.
By listing its securities on the stock exchange, Monogram will be beholden to disclosure, filing and notification requirements, as well as compliance with applicable continued quantitative and qualitative listing standards.
